Avalo Therapeutics

(NASDAQ) CERC

Current PriceN/A

Market CapN/A

Since IPO (2015)-100%

5 Year-100%

1 Year+172%

1 Month-18%

Avalo Therapeutics Financials at a Glance

Market Cap

N/A

Revenue (TTM)

$209.00K

Net Income (TTM)

$78.26M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

CERC News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Avalo Therapeutics

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Garry Arthur Neil, MD

Website

www.avalotx.com

Headquarters

Rockville, MD 20850, US

CERC Financials

Key Financial Metrics (TTM)

Gross Margin

64%

Operating Margin

349%

Net Income Margin

374%

Return on Equity

-78%

Return on Capital

-70%

Return on Assets

-67%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/A

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$0.00

Operating Income

$72.92M

EBITDA

$72.92M

Operating Cash Flow

$51.46M

Capital Expenditure

$0.00

Free Cash Flow

$51.46M

Cash & ST Invst.

$98.34M

Total Debt

$0.00

Avalo Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q4 2025YOY CHG

Revenue

$209.00K

N/A

Gross Profit

$134.00K

N/A

Gross Margin

64.11%

N/A

Market Cap

N/A

Market Cap/Employee

N/A

Employees

N/A

Net Income

$26.87M

N/A

EBITDA

$8.38M

N/A

Quarterly Fundamentals

Name

Q4 2025YOY CHG

Net Cash

$98.34M

-26.9%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-67.20%

N/A

Return on Invested Capital

-70.45%

N/A

Free Cash Flow

$14.25M

N/A

Operating Cash Flow

$14.25M

N/A

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

LUMOLumos Pharma, Inc.

LUMOLumos Pharma, Inc.$4.34+0.00%

PSTIPluristem Therapeutics Inc.

PSTIPluristem Therapeutics Inc.$1.00-2.91%

STSASatsuma Pharmaceuticals, Inc.

STSASatsuma Pharmaceuticals, Inc.$1.10+0.00%

ORKAOruka Therapeutics, Inc.

ORKAOruka Therapeutics, Inc.$62.58-8.52%

GRCEGrace Therapeutics, Inc.

GRCEGrace Therapeutics, Inc.$2.34+4.46%

MGTAMagenta Therapeutics, Inc.

MGTAMagenta Therapeutics, Inc.$0.70-7.74%

LIANYLianBio

LIANYLianBio$0.12+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

INTCIntel

INTCIntel$99.62+0.05%

NOKNokia

NOKNokia$13.30+0.03%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$13.07+0.05%

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF$5.70+0.01%

AAPLApple

AAPLApple$280.14+0.03%

SOUNSoundHound AI

SOUNSoundHound AI$9.56+0.20%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$65.30+0.03%

Questions About CERC

What is the current price of Avalo Therapeutics?

Avalo Therapeutics is trading at N/A per share.

What is the 52-week range for Avalo Therapeutics?

Over the past 52 weeks, Avalo Therapeutics has traded between N/A and N/A.

How much debt does Avalo Therapeutics have?

As of the most recent reporting period, Avalo Therapeutics reported total debt of $2.43M.

How much cash does Avalo Therapeutics have on hand?

Avalo Therapeutics reported $15.89M in cash and cash equivalents in its most recent financial results.

What is Avalo Therapeutics’s dividend yield?

Avalo Therapeutics does not currently have a dividend yield.

Avalo Therapeutics

Avalo Therapeutics Financials at a Glance

CERC News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Avalo Therapeutics

CERC Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Avalo Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About CERC

What is the current price of Avalo Therapeutics?

What is the 52-week range for Avalo Therapeutics?

How much debt does Avalo Therapeutics have?

How much cash does Avalo Therapeutics have on hand?

What is Avalo Therapeutics’s dividend yield?

Premium Investing Services